Erik Schropp is the CEO of Esperante Investments Group and has extensive experience in the pharmaceutical and biotechnology sectors. Currently, they serve on the boards of several companies, including Svar Life Science AB, SEVER Life Sciences, PolyPeptide Group, FinVector Oy, and Esperante Ventures. Erik previously held roles as International Tax & Finance Director at Ferring Pharmaceuticals and Group Financial Officer at C&P Investors Group. They earned a degree in Economics with a focus on Taxation from Erasmus University Rotterdam.
This person is not in the org chart
This person is not in any teams
This person is not in any offices